Hexiris: Founded and Sponsored by Ophthalmologists

Traditional Glaucoma Surgeries

Traditional glaucoma surgeries (trabeculectomy and glaucoma drainage devices), while very effective, are invasive and expensive, require a special skill set, and are accompanied by a long list of complications: devastating eye infections, exposure of a drainage implant, swelling of the cornea, excessively low intraocular pressure (IOP), and double vision. Studies found that incisional surgery in a US hospital typically costs $7,300-$11,300.

Hexiris MIGS Solution

The Hexiris MIGS process is designed to be a safe, fast, easy and less invasive treatment. The process will increase patient satisfaction, present better patient recovery, and increase the sustainability of a health system under pressure from an ageing population.

In addition, it is expected that this medical device and the associated procedure will generate considerable cost benefits for the health system and liberate operating time for ophthalmologists.

Hexiris MIGS Device Highlights

First Injectable Ocular Implant

The Hexiris patented ocular implant device is a game-changer as the first injectable ocular implant that can be processed under an office slit lamp without the complexity and cost of an operating room.

In-Office MIGS

The Hexiris device will be the first of its generation to take glaucoma surgery out of the surgical unit and make it a simple outpatient procedure. The procedure can be performed at the slit lamp by a comprehensive ophthalmologist.

The first device of its kind

This ground-breaking technology will be a scientific first, as there is no current FDA-approved ab-externo MIGS devices (injected from the outside of the eye inward) on the market.